Not Yet RecruitingNot Applicable

Construction of a Comprehensive Health Management Platform for Patients With Cardiovascular-Kidney-Metabolic Syndrome

150 participantsStarted 2026-03

Plain-language summary

Cardiovascular-Kidney-Metabolic (CKM) syndrome underscores the pathophysiologic interplay among metabolic risk factors, chronic kidney disease (CKD) and the cardiovascular system. This crosstalk precipitates multi-organ dysfunction, increases adverse cardiovascular events, and imposes heavy familial and socioeconomic burdens. Building a health-management platform within research wards is therefore urgent. Such a platform is the pivotal venue for assessment, monitoring, intervention and follow-up in continuous care. Leveraging the existing health-management system of the Health Screening Center at Peking University Third Hospital, the investigators will develop a comprehensive CKM platform that integrates systemic inflammatory biomarkers, cardiovascular early-warning algorithms, and personalized diet-and-exercise prescriptions. The system will provide cyclic management encompassing evaluation, guidance, monitoring, feedback and longitudinal follow-up. A randomized controlled trial with two-year prospective follow-up will enroll patients at CKM stages 0-2 to evaluate clinical improvement, quality of life, dietary behavior and physical activity after platform enrollment. The project will enable early identification of high-risk individuals, deliver precision management, maximize data utility, and offer a novel research-ward model that addresses mobile-health pain points and closes the CKM care loop.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CKM stage 0-2 as defined by the American Heart Association CKM diagnostic guidelines * Age 18-75 years * Able to use a smartphone and wearable activity tracker * Willing to sign informed consent and attend scheduled follow-up visits Exclusion Criteria: * CKM stage 3-4 * Acute or critically ill conditions requiring hospitalization * Malignant tumors or any active cancer under treatment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Height

Timeframe: Baseline, Month 12, Month 24

Weight

Timeframe: Baseline, Month 12, Month 24

Systolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Diastolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Heart Rate on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

PR Interval on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QRS Duration on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QTc Interval on 12-Lead Electrocardiogram

Trial details

NCT IDNCT07452029

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

View on ClinicalTrials.gov More Cardiovascular-Kidney-Metabolic Syndrome trials

Plain-language summary

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Height

Timeframe: Baseline, Month 12, Month 24

Weight

Timeframe: Baseline, Month 12, Month 24

Systolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Diastolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Heart Rate on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

PR Interval on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QRS Duration on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QTc Interval on 12-Lead Electrocardiogram